We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Argenta Discovery Announces Contract Drug Discovery Collaboration with CellCentric

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Discovery Announces Contract Drug Discovery Collaboration with CellCentric"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Argenta Discovery Ltd. has announced that it has entered into a fee-for-service collaboration with CellCentric Ltd. Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in virtual screening, molecular biology, biochemical assay development and in vitro screening, to discover inhibitors for two potential epigenetic-related therapeutic targets.

Commenting on the agreement, Dr Christopher Ashton, Argenta’s Chief Executive, said, “We are pleased that CellCentric has chosen to collaborate with Argenta on these interesting projects.  Their decision to work with us is based on our contract drug discovery team’s acknowledged expertise in hit identification and assay development.  We look forward to building a successful and long-term partnership with CellCentric.”

Dr Will West, Chief Executive Office at CellCentric said, "We are looking forward to working with Argenta Discovery. They have a good reputation in contract drug discovery and we are confident they have the necessary skills and experience to advance these epigenetic-related projects on behalf of CellCentric, and will deliver to the agreed timelines. We anticipate using Argenta’s know-how in hit identification and assay development and screening will help us advance CellCentric’s knowledge and expertise in epigenetic research.”

Financial terms of the deal were not disclosed, but the agreement does provide options to expand the relationship.